Popular Articles

Phase 3 Trial Initiated To Evaluate Combination Therapy Of Nexavar(R) And Tarceva(R) In Patients With Liver Cancer
Bayer HealthCare LLC., Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Roche today announced the initiation of a Phase 3 trial examining Nexavar(R) (sorafenib) tablets in combination with Tarceva(R) (erlotinib) tablets as a potential new treatment option for patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer.
generic viagra online
RCOG Releases New Model For Medical Revalidation
The Royal College of Obstetricians and Gynaecologists (RCOG) has released a new model for medical revalidation this week.
News of the day
Prereg Tutor Training Day And Prereg Trainee Pharmacist Programme 2009/10 - Booking Now
Registration forms for the prereg trainee pharmacist programme 2009/10 are now available to download on the NPA members" website. The NPA is also providing training on 26 June 2009 for prereg tutors that have enrolled their prereg on to the NPA"s programme.
Endocrinology

J & J: Hospital Deal Will Hurt Medical Device Sales

The CFO for Johnson & Johnson"s said President Obama"s deal with hospitals to cut Medicare costs will reduce the sales of medical devices, Bloomberg reports: "Hospitals buy medical devices, including J&J"s artificial hips and stents to prop open clogged arteries, directly from the manufacturer, (Johnson and Johnson CFO Dominic) Caruso said today in an interview with Bloomberg News. The hospitals are reimbursed by government-run health plans for the cost of a procedure regardless of the price of the equipment, pressuring hospitals to cut purchases of the latest technologies, he said. ò€¦ "The deal that the hospital industry struck will obviously have an impact on the medical-device business," Caruso said. "Medicare reimburses the hospital for a basket of costs related to a procedure, of which medical devices are included"" (Randall, 7/14). Caruso"s comments come on the day Johnson & Johnson revealed that its 2nd quarter profits fell 3.5 percent, The Associated Press reports in a separate story. "Still, the company beat Wall Street"s expectations, as the firm reduced spending on sales, administration and research by about 13 percent and production costs by 6 percent." The company blamed generic competition, the global recession and a stronger dollar on its showing (Johnson, 7/14). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):